RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

This study is testing a new treatment sequence for elderly patients with a particularly aggressive subtype of large B-cell lymphoma called double expressor lymphoma (DEL), where two cancer-promoting proteins (MYC and BCL2) are both overactive. Researchers are testing a combination of targeted drugs followed by a modified version of standard chemotherapy. **You may be eligible if...** - You are 70 or older, OR 65 to 69 with reduced physical function (ECOG ≥ 2) - You have newly diagnosed diffuse large B-cell lymphoma (DLBCL) confirmed by biopsy - Your tumor shows overexpression of both MYC and BCL2 proteins (double expressor) - You have at least one measurable area of disease - You have not previously been treated for this lymphoma **You may NOT be eligible if...** - You have a transformed or other subtype of lymphoma that doesn't meet the study criteria - Your organ function (heart, kidneys, liver) is too poor to tolerate chemotherapy - You have an active serious infection or other condition making treatment too risky Talk to your doctor to see if this trial is right for you.